---

CASE PRESENTATION: RHEUMATIC HEART DISEASE (MITRAL STENOSIS)

For Final Year MD General Medicine Resident - Grand Round Presentation

---

PART I: CASE PRESENTATION

---

PRESENTING THE CASE TO THE PROFESSOR

"Good morning sir/ma'am. I am presenting a case of a 28-year-old female admitted to our ward with complaints of breathlessness on exertion for 3 years, progressively worsening over the last 2 months, with one episode of hemoptysis 15 days ago."

---

HISTORY

1. PRESENTING COMPLAINTS

---

2. HISTORY OF PRESENTING ILLNESS

• Insidious onset, 3 years ago, initially on moderate exertion (climbing 2 flights of stairs, walking >500 m) - NYHA Class II
• Progressed over the last 2 months to occur on minimal exertion (walking 100 m on flat ground) - NYHA Class III
• Associated with 2 pillow orthopnea; no paroxysmal nocturnal dyspnea (PND) initially, but 2 episodes of PND in the last 3 weeks
• No wheeze, no fever with breathlessness

• Intermittent, irregular, fast heartbeats for 2 years
• No presyncope or syncope associated

• Bilateral, pitting, more towards evening, relieving partially by morning
• No facial puffiness, no abdominal distension (no ascites history)

• Single episode, 15 days ago
• Approximately 1 teaspoon of bright red blood, mixed with sputum
• No foul smell, no TB contact history
• No recurrence

---

3. PAST HISTORY - CRITICAL SECTION

"Sir, this patient gives a very relevant past history that directly links to her current cardiac condition."

• History of recurrent sore throats during childhood (ages 8-14 years), approximately 3-4 episodes per year, treated with oral antibiotics (likely penicillin or amoxicillin)
• History of acute rheumatic fever at age 12 years - treated in a government hospital with penicillin injection; was told she had "heart involvement" at that time
• History of joint pains involving knees, ankles, wrists - migratory, self-limiting (typical of rheumatic arthritis)
• She did NOT receive regular benzathine penicillin prophylaxis after the ARF episode (this is a very common history in endemic regions)
• No history of hypertension, diabetes mellitus, tuberculosis, thyroid disease
• No previous cardiac surgery or catheterization

---

4. MENSTRUAL AND OBSTETRIC HISTORY

• Menarche at 14 years, regular cycles 28/4
• LMP 10 days ago; not pregnant currently
• P1L1 - one delivery 3 years ago, had increased breathlessness during pregnancy (NYHA Class III in 3rd trimester), managed medically; postpartum breathlessness partially improved
• No history of spontaneous abortions

"Sir, this is important because worsening of mitral stenosis during pregnancy is a well-recognized phenomenon due to the 40-50% increase in blood volume and heart rate, which increases the gradient across the mitral valve."

---

5. FAMILY HISTORY

• No family member with known cardiac disease
• Elder sister had rheumatic fever in childhood, currently asymptomatic

---

6. PERSONAL & SOCIAL HISTORY

• Housewife from a semi-urban area
• Lower socioeconomic status; overcrowded household (6 members, 2-room dwelling)
• Non-smoker, no alcohol, no drug abuse
• Diet: mixed, adequate
• No significant occupational exposure

"Sir, the socioeconomic and environmental background is relevant - overcrowding and poverty are major risk factors for repeated Group A Streptococcal pharyngitis and thus rheumatic fever in endemic regions."

---

PHYSICAL EXAMINATION

GENERAL EXAMINATION

"On general examination, the patient is..."

• Conscious, cooperative, well-oriented to time, place, and person
• Built and nourishment: Moderately built, adequately nourished (BMI ~20 kg/m²)
• Pallor: Mild pallor present (contributing to dyspnea)
• Icterus: Absent
• Cyanosis:
  • Peripheral cyanosis: Absent at rest
  • Central cyanosis: Absent
  • Malar flush: Present - reddish-purple discoloration over malar eminences bilaterally (due to pulmonary hypertension causing peripheral vasoconstriction with local vasodilation in malar area)
• Clubbing: Absent (important - clubbing is NOT a feature of pure MS)
• Lymphadenopathy: No cervical, axillary, or inguinal lymph nodes palpable
• Edema: Bilateral pitting pedal edema, Grade 2 (up to mid-shin), pitting, non-tender
• JVP: Elevated - 5 cm above sternal angle (normal ≤3 cm); prominent 'a' wave (if in sinus rhythm - suggests raised RVEDP) OR absent 'a' wave with irregular venous pulsation (if in AF)

---

VITAL SIGNS

"Sir, the pulse is irregularly irregular, which suggests atrial fibrillation - this is the most common arrhythmia complicating mitral stenosis, occurring in up to 40% of patients with severe MS."

---

CARDIOVASCULAR EXAMINATION

INSPECTION

• No visible apical impulse
• No precordial bulge (rules out childhood cardiac enlargement)
• No visible pulsations over the base of the heart

PALPATION

"Sir, the TAPPING apical impulse is a hallmark of mitral stenosis - it represents a palpable, loud first heart sound due to sudden tensing of the stiff, calcified mitral valve."

PERCUSSION

• Right border of cardiac dullness displaced rightward (to right sternal border) - right atrial enlargement
• Upper border of cardiac dullness elevated to 2nd ICS left parasternal - pulmonary artery dilation

AUSCULTATION (The most important part - practice presenting this confidently)

"On auscultation of the precordium, I found the following:"

• Loud P2: Indicates pulmonary hypertension
• Graham Steell murmur: Early diastolic, high-pitched blowing murmur at left sternal border (2nd-3rd ICS) due to pulmonary regurgitation secondary to pulmonary hypertension

• Pansystolic murmur at LLSB increasing with inspiration (Carvallo's sign): Functional tricuspid regurgitation due to RV dilation from pulmonary hypertension

---

RESPIRATORY EXAMINATION

• Percussion note: Dull at bilateral lung bases (small pleural effusions)
• Auscultation: Fine crepitations at bilateral lung bases (pulmonary venous congestion)
• No wheeze

ABDOMINAL EXAMINATION

• Soft, non-tender
• Liver: Palpable 2 cm below right costal margin, tender, smooth surface - mild congestive hepatomegaly
• Spleen: Not palpable
• No free fluid (ascites) - early stage

---

SUMMARY OF EXAMINATION FINDINGS

"To summarize, Sir - this 28-year-old female from an endemic background has malar flush, irregularly irregular pulse, tapping non-displaced apical impulse, left parasternal heave, palpable P2, loud S1, opening snap, mid-diastolic rumble with pre-systolic accentuation (absent currently due to AF), Graham Steell murmur, and signs of right heart failure. This clinical picture is consistent with severe rheumatic mitral stenosis with secondary pulmonary hypertension, functional tricuspid regurgitation, and atrial fibrillation."

---

INVESTIGATIONS

ELECTROCARDIOGRAM (ECG)

• Atrial Fibrillation: Absent P waves, irregular R-R intervals, fibrillatory baseline
• If sinus rhythm: P-mitrale - bifid, notched P wave in lead II (duration >0.12 sec), biphasic in V1 (negative terminal deflection >1 mm × 1 mm)
• Right axis deviation (due to RVH)
• Right ventricular hypertrophy: R>S in V1, deep S in V6, tall R in aVR

CHEST X-RAY (PA VIEW)

ECHOCARDIOGRAPHY (2D + DOPPLER) - Gold Standard

• Thickened, calcified mitral valve leaflets
• Restricted leaflet opening - "hockey stick" or "elbow" deformity of anterior mitral leaflet
• Doming of anterior mitral leaflet
• MVA (Mitral Valve Area) by planimetry: Severe MS <1.0 cm²
• Left atrial enlargement (LA dimension >4.5 cm)
• LA thrombus - especially in left atrial appendage (if present, contraindications MBV)
• RV dilation and dysfunction
• Wilkins score (each 1-4 for leaflet mobility, thickening, calcification, subvalvular thickening): Score ≤8 = favorable for balloon valvotomy

• Mean gradient across mitral valve: >10 mmHg (severe)
• MVA by pressure half-time (PHT) = 220/PHT (normal >4 cm², severe <1 cm²)
• Estimated RVSP (proxy for pulmonary artery systolic pressure) >50 mmHg

SEVERITY GRADING OF MS (AHA/ACC)

OTHER INVESTIGATIONS

• CBC: May show mild anemia (dilutional or iron deficiency)
• ESR, CRP, ASO titer: If ARF activity suspected
• Throat swab: If active infection suspected
• PT/INR: Baseline, prior to warfarin therapy
• Renal and liver function tests: Baseline and to assess congestion
• Thyroid function: To rule out thyrotoxicosis as cause of AF
• Blood culture: If infective endocarditis suspected

---

DIAGNOSIS

"Based on the history of rheumatic fever, clinical findings, ECG, CXR, and echocardiography, this patient has:

1. Pulmonary arterial hypertension (moderate-severe)
2. Atrial Fibrillation (permanent)
3. Functional tricuspid regurgitation (moderate)
4. NYHA Class III dyspnea
5. Congestive cardiac failure (biventricular)"*

---

MANAGEMENT

IMMEDIATE MANAGEMENT

1. Propped-up position, supplemental oxygen to maintain SpO₂ >95%
2. Rate control in AF: IV/oral digoxin (loading dose 0.5 mg then 0.25 mg 8-hourly × 2 doses, then 0.25 mg OD) OR oral metoprolol 25-50 mg BD (avoid beta-blockers if low cardiac output)
3. Diuresis: Furosemide 40 mg IV for pulmonary congestion
4. Anticoagulation: Heparin infusion/LMWH → transition to Warfarin (target INR 2.0-3.0) - mandatory for MS + AF due to very high embolic risk. NOACs are contraindicated in rheumatic MS + AF (no evidence, and the INVICTUS trial showed rivaroxaban inferior to warfarin in this setting)

LONG-TERM MEDICAL MANAGEMENT

1. Diuretics: Furosemide ± spironolactone (for edema and pulmonary congestion)
2. Rate control: Digoxin + beta-blocker
3. Anticoagulation: Warfarin lifelong (INR 2-3)
4. Penicillin prophylaxis: Benzathine penicillin G 1.2 million units IM every 3-4 weeks for secondary prophylaxis against Group A Streptococcal infection
   • Duration: Until age 40 (or lifelong if carditis present) per WHO/AHA guidelines
5. Antibiotic prophylaxis for IE: For dental/surgical procedures as per current guidelines
6. Salt restriction and fluid monitoring

INTERVENTIONAL/SURGICAL MANAGEMENT

• Procedure of choice if Wilkins score ≤8
• Transseptal (antegrade) approach; Inoue balloon catheter
• Separates fused commissures
• Results in doubling of MVA, halving of gradient
• Contraindications: LA thrombus, MR >2+, Wilkins score >8, significant calcification, severe subvalvular disease

• Open mitral commissurotomy (OMC): When morphology suboptimal for PBMV
• Mitral valve replacement (MVR): Mechanical valve (lifelong anticoagulation) or bioprosthetic (no anticoagulation needed after 3 months but less durable)
• Mechanical valve preferred in young patients needing MVR given durability; patient already needs anticoagulation for AF

---

PART II: VIVA QUESTIONS WITH ANSWERS

---

VIVA Q1: What is the pathophysiology of mitral stenosis?

1. ↑ LA pressure → LA dilation
2. ↑ Pulmonary venous pressure → pulmonary congestion (dyspnea, orthopnea, hemoptysis)
3. ↑ Pulmonary arterial pressure (reactive pulmonary hypertension)
4. RV pressure overload → RVH → RV dilation → functional TR
5. ↓ LV filling → ↓ cardiac output → fatigue, exertional dyspnea
6. LA dilation → atrial fibrillation → LA thrombus → systemic embolism

---

VIVA Q2: What are the causes of hemoptysis in mitral stenosis?

---

VIVA Q3: Describe the auscultatory findings in mitral stenosis in detail.

• Due to forceful closure of thickened but mobile mitral leaflets
• Wide excursion of leaflets due to high LA-LV pressure difference
• Disappears with calcification (immobile leaflets)

• Early diastolic sound, high-pitched
• Best heard: left sternal border, 4th ICS, with diaphragm
• Mechanism: sudden tensing of thickened leaflets at full excursion after doming
• S2-OS interval (A2-OS): inversely proportional to severity (shorter = more severe)
  • A2-OS <0.06 sec = severe MS (high LA pressure opens valve earlier)
  • A2-OS >0.10 sec = mild MS
• Absent when: valve heavily calcified, concomitant AR (equalizes LA-LV pressure faster)

• Low-pitched, rumbling, best heard at apex in left lateral decubitus position with BELL of stethoscope
• Duration correlates with severity (longer = more severe)
• Accentuated by mild exercise (increases transvalvular flow)

• Crescendo component just before S1
• Present ONLY in sinus rhythm (atrial systole increases flow across valve)
• Absent in AF

---

VIVA Q4: What is the Wilkins score? How does it guide management?

• ≤8: Favorable morphology → PBMV preferred (good result expected)
• 9-11: Intermediate; selective use of PBMV
• ≥12: Unfavorable → surgical intervention preferred (MVR or commissurotomy)

---

VIVA Q5: What are the 2015 Revised Jones Criteria for diagnosis of Acute Rheumatic Fever?

---

VIVA Q6: Why are NOACs contraindicated in rheumatic MS with AF? What anticoagulant should be used?

1. All landmark NOAC trials (RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE) excluded patients with moderate-severe MS - no safety/efficacy data
2. The INVICTUS trial (NEJM 2022) specifically tested rivaroxaban vs. warfarin in rheumatic heart disease with AF: rivaroxaban was inferior to warfarin (higher stroke/death rate)
3. Thrombus risk in MS+AF is particularly high (stagnant flow in dilated LA) and requires very reliable anticoagulation

• Target INR: 2.0 - 3.0
• Mechanical valve: 2.5-3.5
• Must be monitored regularly with INR
• LMWH/UFH as bridging

---

VIVA Q7: How do you classify the severity of pulmonary hypertension in MS? What is reactive vs. passive pulmonary hypertension?

1. Passive (Postcapillary) PH: Direct backward transmission of elevated LA pressure to pulmonary veins and pulmonary capillaries. This is fully reversible after intervention (PBMV or MVR).
2. Reactive (Precapillary) PH: Superimposed pulmonary arteriolar vasoconstriction and intimal/medial hypertrophy due to chronic PH. This "protective" response reduces the pulmonary capillary hydrostatic pressure (partially protecting the patient from pulmonary edema) but at the cost of RV pressure overload.
   • Characterized by "out-of-proportion" PH (PVRI >3 Wood units after accounting for PCWP)
   • Partly reversible after intervention but may persist

---

VIVA Q8: What is the Duroziez sign, Austin Flint murmur, and De Musset's sign? (For mixed valvular disease viva)

---

VIVA Q9: What is secondary prophylaxis for Rheumatic Fever? When should it be stopped?

---

VIVA Q10: What ECG changes are seen in mitral stenosis? What is P-mitrale?

• Lead II: Broad, notched ('M-shaped') P wave with duration >0.12 sec (120 ms); inter-peak interval >40 ms
• Lead V1: Biphasic P wave with prominent negative terminal deflection (>1 mm deep AND >1 mm wide = 1 small square)
• Mechanism: delayed activation of the enlarged left atrium

---

VIVA Q11: Differentiate Mitral Stenosis from Mitral Regurgitation on clinical examination.

---

VIVA Q12: What is the Lutembacher syndrome?

• The ASD provides a "pop-off" valve for the elevated LA pressure
• Blood shunts from LA → RA (left-to-right) due to elevated LA pressure
• This REDUCES the gradient across the mitral valve (misleadingly mild MS on echo)
• But causes significant right heart volume overload (RA, RV dilation)

• Symptoms of MS may be less severe than expected
• Signs of large ASD predominate: wide fixed split S2, pulmonary flow murmur
• Pulmonary hypertension develops from combined LA HTN + increased pulmonary flow
• Eventually Eisenmenger syndrome can occur

---

STANDARD TEXTBOOK REFERENCES

---

TIPS FOR THE VIVA PRESENTATION

1. Always present findings in the order: General → Vitals → CVS (Inspection → Palpation → Percussion → Auscultation) → Respiratory → Abdomen
2. Mention "Sir" while making key points to draw the examiner's attention
3. Justify each finding - don't just list, but say "which suggests..."
4. Know your echo numbers cold: MVA severe <1 cm², PASP >50 severe PH, Wilkins ≤8 for PBMV
5. The A2-OS interval question is a classic trap - shorter = MORE severe (higher LA pressure = earlier opening)
6. NOACs in rheumatic AF is a hot viva topic - know the INVICTUS trial
7. Pre-systolic accentuation absent in AF - examiners often ask why
8. Secondary prophylaxis duration must be memorized
9. When asked "what else would you look for" - always check for signs of infective endocarditis (splinter hemorrhages, Osler nodes, Janeway lesions, Roth spots) in ANY valvular disease patient
10. If examiner asks "what is the most common cause of death in MS?" - answer: Heart failure, followed by systemic embolism, pulmonary complications, IE

---

CASE PRESENTATION: FIBROCAVITARY LESION OF THE LUNG

For Final Year MD General Medicine Resident - Grand Round Presentation

---

UNDERSTANDING THE TOPIC FIRST

What is a Fibrocavitary Lesion? A fibrocavitary lesion is a radiological and pathological entity characterized by a lung cavity (air-containing space within lung parenchyma with a wall >1 mm thick) surrounded by or associated with fibrosis. The classical context in Indian medicine is post-primary tuberculosis, but the differential is broad.

---

PART I: CASE PRESENTATION

---

PRESENTING THE CASE TO THE PROFESSOR

"Good morning Sir/Ma'am. I am presenting a case of a 35-year-old male farmer from a rural background who was admitted with chief complaints of cough with expectoration for 3 months, hemoptysis for 15 days, low-grade fever with evening rise for 2 months, and significant weight loss of approximately 8 kg over 3 months."

---

HISTORY

1. PRESENTING COMPLAINTS

---

2. HISTORY OF PRESENTING ILLNESS

• Insidious onset, initially dry, progressed to productive within 2 weeks
• Sputum: mucopurulent, yellowish-green, approximately 2-3 tablespoons per day
• No foul smell to sputum (important - foul smell suggests anaerobic infection/lung abscess)
• Worsens in the mornings (postural drainage effect)
• No change with antibiotic courses tried outside (two courses of amoxicillin and azithromycin - no improvement)

• Onset 15 days ago, initially streaky blood mixed with sputum
• Progressed to bright red blood, approximately 50-100 mL per episode
• 3-4 episodes over the last 15 days
• No choking, no blood in stool, no urinary bleeding
• This is a red flag symptom - persistent hemoptysis >100 mL/day constitutes massive hemoptysis

• Evening rise of temperature (typically 99-100°F in the evenings, patient notes feverishness daily after 4 PM)
• Drenching night sweats - patient changes clothes at night; soaking sheets
• Anorexia - complete loss of appetite for 2 months
• Weight loss - estimated 8 kg over 3 months (significant, >5% body weight in 1 month)

• Mild exertional breathlessness, NYHA/MRC Grade 2
• No orthopnea, no paroxysmal nocturnal dyspnea
• Worsens during episodes of hemoptysis

---

3. PAST HISTORY - CRITICAL SECTION

"Sir, the past history in this patient is extremely relevant to establishing the etiology of his fibrocavitary lesion."

• History of tuberculosis: Patient was treated for pulmonary TB 8 years ago - completed a 6-month DOTS regimen (Category 1: 2HRZE + 4HR). Was declared sputum-negative and "cured" at that time.
• No regular follow-up after TB treatment completion
• History of diabetes mellitus for the last 3 years - on irregular treatment (metformin), poor glycemic control (not monitoring regularly)
• No history of hypertension, heart disease, malignancy
• No history of prolonged steroid use, immunosuppressive drugs
• No history of HIV (will investigate)

"Sir, this prior TB history followed by new symptoms in a diabetic patient raises the important possibility of TB reactivation/recurrence, or alternatively, a complication of the old TB cavity (aspergilloma, or secondary bacterial superinfection)."

---

4. DRUG AND TREATMENT HISTORY

• Metformin 500 mg BD (irregular compliance)
• Multiple antibiotics tried as outpatient (amoxicillin, azithromycin) - no improvement
• No anti-TB drugs currently
• No steroids, no biologics, no immunosuppressants

---

5. PERSONAL AND SOCIAL HISTORY

• Occupation: Farmer, heavy manual worker
• Residence: Rural area, joint family, 8 members in a small house (overcrowding - significant TB risk factor)
• Smoking: 15 pack-years (15 cigarettes/day for 15 years) - increases risk of COPD, malignancy, TB susceptibility
• Alcohol: Regular alcohol use, approximately 90-120 mL of country liquor daily for 10 years (alcoholism - major risk factor for TB reactivation, aspiration lung abscess)
• Diet: Irregular, nutritionally inadequate (another TB risk factor)
• Contact history: Lives with elderly parents; elder brother treated for TB 5 years ago - direct household TB contact

---

6. FAMILY HISTORY

• Elder brother: TB (treated 5 years ago)
• Father: Diabetes mellitus
• No family history of malignancy

---

7. REVIEW OF SYSTEMS

---

PHYSICAL EXAMINATION

GENERAL EXAMINATION

"On general examination, the patient is..."

• Conscious, cooperative, oriented to time, place, person
• Built and nourishment: Poorly nourished, wasted, BMI ~16.5 kg/m² (underweight - BMI <18.5)
• Pallor: Moderate pallor (chronic disease + hemoptysis)
• Icterus: Absent
• Cyanosis: Absent at rest (peripheral and central)
• Clubbing: (Critical finding) - Grade 3 Clubbing bilaterally - loss of nail bed angle, fluctuation of nail bed, increased curvature of nails (Clubbing in fibrocavitary disease suggests chronic suppurative lung disease, bronchiectasis, empyema, or malignancy as complications; NOT typical of uncomplicated TB)
• Lymphadenopathy: Left cervical lymphadenopathy - single node, 2 × 2 cm, firm, non-tender, rubbery, discrete, not matted, no overlying skin changes (Strongly suggests tuberculous lymphadenitis - needs FNAC)
• Edema: Absent
• Jaundice: Absent
• JVP: Not raised

---

VITAL SIGNS

---

RESPIRATORY EXAMINATION - DETAILED

INSPECTION

• Chest shape: Asymmetrical - left upper chest appears flattened/sunken (fibrosis causing volume loss in left upper zone)
• Trachea: Deviated to the LEFT (toward the side of the lesion - volume loss/fibrosis pulls trachea ipsilaterally)
• Intercostal spaces: Narrowed on the left upper zone (fibrosis)
• Apex beat: May be displaced (pulled left by fibrosis)
• Respiratory movements: Reduced on the left side, particularly upper zone
• Use of accessory muscles: Present (scalene, sternomastoid) - suggests significant lung involvement

"Sir, the combination of ipsilateral tracheal deviation, flattened chest, and reduced movements on the same side points to upper lobe fibrosis - the hallmark of post-primary TB or old fibrocavitary disease on the left side."

PALPATION

PERCUSSION

"Sir, the cracked-pot resonance or 'bruit d'airain' is a very specific percussion sign over a large pulmonary cavity - produced when the cavity communicates with a bronchus and has an open mouth."

AUSCULTATION - MOST CRITICAL PART

• Bilateral scattered crackles in mid-zones (bronchogenic spread - "satellite lesions")
• Reduced breath sounds at left base (if small pleural effusion present)

"Sir, the combination of bronchial breathing + post-tussive crepitations + amphoric breathing in the left upper zone is the classical auscultatory triad of a pulmonary cavity with surrounding consolidation - in this clinical context, strongly pointing to fibrocavitary tuberculosis."

---

CARDIOVASCULAR EXAMINATION

• Heart rate: 96/min, regular
• No murmurs
• No signs of cor pulmonale at this stage

ABDOMINAL EXAMINATION

• Abdomen soft, non-tender
• Liver 2 cm palpable (alcoholic hepatomegaly vs. amyloidosis as complication of chronic TB)
• No splenomegaly
• No free fluid

---

SUMMARY OF CLINICAL FINDINGS

"To summarize Sir - this 35-year-old male with history of prior TB, diabetes, alcoholism, and household TB contact presents with 3 months of productive cough, evening pyrexia, night sweats, massive weight loss, and hemoptysis. On examination, he has pallor, clubbing, left cervical lymphadenopathy, a flattened left upper chest with ipsilateral tracheal deviation, reduced movements, increased vocal fremitus, dullness, bronchial breathing, and amphoric breath sounds over the left upper zone, with coarse post-tussive crepitations. This clinical picture is consistent with fibrocavitary disease of the left upper lobe. The most likely diagnosis is post-primary pulmonary tuberculosis with fibrocavitary disease. However, other causes including aspergilloma in an old TB cavity, secondary bacterial infection/lung abscess, and rarely lung malignancy must be considered."

---

INVESTIGATIONS

BEDSIDE INVESTIGATIONS

1. Sputum examination (×3 samples):
   • Morning, spot, morning sequence
   • Gram stain: Rule out bacterial superinfection
   • ZN (Ziehl-Neelsen) stain for AFB: 3+ AFB seen (strongly positive)
   • Sputum culture: Lowenstein-Jensen (L-J) medium (takes 6-8 weeks)
   • Cartridge-Based NAAT (CBNAAT/GeneXpert MTB/RIF): Detects MTB DNA AND rifampicin resistance within 2 hours - first-line test per NTEP India guidelines
2. Mantoux test (TST):
   • PPD 5TU intradermal; read at 48-72 hours
   • Induration ≥10 mm = positive in normal host
   • ≥5 mm = positive in HIV/immunocompromised
   • Caveat: In severely immunocompromised or advanced TB, may be falsely negative (anergy)

---

BLOOD INVESTIGATIONS

---

CHEST X-RAY (PA VIEW) - KEY RADIOLOGICAL FINDINGS

"Sir, the chest X-ray is the most important initial investigation in a patient with suspected fibrocavitary disease."

• Ring shadow with air crescent sign (if aspergilloma forms)
• Fluid level inside cavity = secondary infection

---

HIGH-RESOLUTION CT (HRCT) CHEST

• Thick-walled (>3 mm) irregular cavity in upper lobes
• Tree-in-bud pattern (centrilobular nodules with branching lines = endobronchial spread)
• Consolidation, ground-glass opacification
• Bronchiectasis in same lobe
• Fibrous bands, traction bronchiectasis
• Air crescent sign (aspergilloma - mobile intracavitary mass that moves with position)
• Mediastinal lymphadenopathy with central low density (caseous necrosis - ring enhancement on contrast)

---

BRONCHOSCOPY

• Sputum smear negative cases
• To rule out endobronchial lesion/carcinoma
• BAL for AFB, cytology, culture in smear-negative cases
• To identify the bleeding site in massive hemoptysis

---

INVESTIGATIONS FOR COMPLICATIONS

---

DIAGNOSIS

1. Hemoptysis (moderate) - likely from erosion of bronchial artery in cavity wall
2. Type 2 Diabetes Mellitus - poor control (HbA1c 9.5%)
3. Alcoholic liver disease (mild)
4. Cervical lymphadenopathy - likely TB lymphadenitis (for FNAC)
5. Anemia of chronic disease

---

MANAGEMENT

IMMEDIATE MANAGEMENT

1. Bed rest in lateral decubitus position - affected side DOWN (prevents blood from flooding the good lung)
2. IV access; oxygen supplementation
3. IV tranexamic acid 500 mg TDS (antifibrinolytic)
4. Vasopressin/terlipressin: vasoconstrictive effect on bronchial arteries
5. If massive (>300 mL/day): Bronchial artery embolization (BAE) - interventional radiology; first-line for life-threatening hemoptysis
6. Rigid bronchoscopy: For localization and temporary balloon tamponade
7. Surgical resection (pneumonectomy/lobectomy): Last resort

---

ANTI-TUBERCULOSIS TREATMENT (ATT)

• This is a retreatment case (previously treated TB returning with symptoms)
• Must send for CBNAAT first to detect rifampicin resistance before starting treatment
• If rifampicin sensitive: Category 2 regimen

---

MANAGEMENT OF DIABETES + TB (Important Viva Topic)

• Optimize glycemic control - start/intensify insulin therapy (metformin less ideal with liver disease/infections)
• Poor glycemic control increases TB progression, increases drug-resistant TB risk, slows sputum conversion
• Rifampicin induces CYP450 - reduces plasma levels of sulfonylureas; insulin preferred
• Monitor HbA1c every 3 months during ATT

---

MANAGEMENT OF ASPERGILLOMA (If Confirmed)

• Asymptomatic: Observation, antifungal prophylaxis debated
• Hemoptysis: Bronchial artery embolization (immediate)
• Surgical resection: Definitive treatment for localized disease in fit patients
• Voriconazole (preferred over itraconazole) for systemic aspergillosis

---

INFECTION CONTROL

• Airborne isolation (negative-pressure room)
• N95 mask for healthcare workers
• Contact tracing for household members (screening for active/latent TB)

---

PART II: VIVA QUESTIONS WITH ANSWERS

---

VIVA Q1: What is a fibrocavitary lesion? Enumerate its causes.

• Primary bronchogenic carcinoma (squamous cell carcinoma - most common malignant cause of cavitation; thick, irregular inner wall)
• Metastatic malignancy (especially squamous cell metastasis; multiple thin-walled cavities)

• Granulomatosis with polyangiitis (Wegener's) - bilateral cavitating nodules
• Rheumatoid nodules
• Sarcoidosis (rare)

• Pulmonary infarction with cavitation
• Bullae (emphysematous) - thin-walled, no fibrosis
• Hydatid cyst with water lily sign (Camalote sign)
• Traumatic pneumatocele

---

VIVA Q2: Describe the pathogenesis of cavitation in tuberculosis.

• The caseous center remains solid initially (if immunity good)
• Reactivation/progressive disease: Proteolytic enzymes (matrix metalloproteinases, bacterial proteases) cause liquefaction of the caseous necrosis
• The liquefied material is an excellent growth medium - bacillary load jumps from ~10⁴ to 10⁹-10¹⁰ bacilli in liquefied caseous focus (the highest bacterial burden in the body)

• The liquefied caseous plug erodes through the wall of an adjacent bronchus
• The necrotic material drains out through the bronchus → patient produces the classic "dirty," mucopurulent sputum
• Air enters → Cavity forms (air-filled space replacing the former caseous focus)

• Bronchogenic spread: Infected sputum carries bacilli to other areas of same and opposite lung → "satellite" lesions, tree-in-bud pattern
• Rasmussen's aneurysm: A bronchial artery within the cavity wall undergoes inflammatory weakening and dilates → massive hemoptysis when it ruptures
• Secondary infection: Bacterial colonization, aspergilloma
• Bronchopleural fistula: Cavity ruptures into pleural space → pneumothorax, empyema

• Higher pO₂ (apex: ~150 mmHg vs. base: ~90 mmHg) - MTB is an obligate aerobe
• Poor lymphatic drainage
• Less macrophage activity due to lower blood flow

---

VIVA Q3: How do you differentiate a TB cavity from a lung abscess clinically and radiologically?

---

VIVA Q4: What is Rasmussen's aneurysm? What is its clinical significance?

• In a long-standing TB cavity, the wall contains granulation tissue and inflammatory cells
• Adjacent branches of the pulmonary artery (occasionally bronchial artery) are incorporated into the cavity wall
• Chronic inflammation weakens the arterial wall → progressive dilation → pseudoaneurysm formation
• The aneurysm projects into the cavity lumen

• Massive, life-threatening hemoptysis when the aneurysm ruptures
• Accounts for a significant proportion of cases of massive hemoptysis in TB patients
• Estimated incidence: 5% of fibrocavitary TB cases
• Mortality from rupture: 50-100% if untreated

• Bronchial Artery Embolization (BAE): First-line emergency treatment for control of bleeding
• CT angiography: To identify the aneurysm and feeding vessel
• Surgical resection: Definitive treatment in stable patients

• Rasmussen's: Large vessel, arterial-pressure bleed, usually pulmonary artery branch
• Aspergilloma: Mechanical irritation by mycetoma + enzymatic damage to cavity wall vessels

---

VIVA Q5: What is an aspergilloma? How does it present in the context of fibrocavitary TB?

• Residual TB cavity post-treatment provides the perfect nidus
• Aspergillus fumigatus spores colonize the cavity wall
• Grow as a free-floating intracavitary mass
• The mass moves with gravity changes (positional mobility on CT)

• Often asymptomatic for years
• Hemoptysis: Most important symptom (occurs in 50-80% of cases; can be life-threatening)
• Mechanism of hemoptysis: Mechanical trauma to cavity wall by the moving mycetoma + enzymatic damage to blood vessels by Aspergillus proteases
• Cough, weight loss

• Monod sign (Air crescent sign): Crescent-shaped lucency between the mycetoma and the upper cavity wall on CXR/CT
• The fungus ball is seen as a mobile, dependent, rounded opacity within a cavity - it changes position with posture (confirmed on decubitus CXR or CT)

• Serum Aspergillus IgG precipitins (positive in >90% of cases)
• Sputum fungal culture
• CT chest with contrast (best characterization)
• Serum galactomannan (more useful for invasive aspergillosis)

• Asymptomatic small aspergilloma: Observation (antifungals not very effective for simple aspergilloma)
• Hemoptysis: Bronchial artery embolization (emergency); voriconazole for adjunct
• Symptomatic/recurrent hemoptysis: Surgical resection (lobectomy) - definitive

---

VIVA Q6: What are the causes and approach to massive hemoptysis?

• Most widely used: >300 mL of blood in 24 hours (Rosen's Emergency Medicine)
• Other definitions: >200 mL/24-48 hrs (Miller's Anesthesia); >600 mL/24h (some texts)
• More practically: any hemoptysis that threatens the airway or is hemodynamically significant

• Position: Lateral decubitus with bleeding lung DEPENDENT (prevents aspiration into good lung)
• Supplemental oxygen, IV access
• Intubation if airway threatened (double-lumen ET tube to isolate bleeding lung)

• IV fluids, blood transfusion if needed
• Correct coagulopathy (FFP, platelets)
• Withhold anticoagulants

• IV Tranexamic acid (antifibrinolytic) 500 mg TDS
• Terlipressin (vasoconstrictor) - reduces pulmonary circulation
• Morphine: Suppresses cough reflex, reduces hemoptysis
• Vasopressin analog: For bronchial artery vasospasm

• Rigid bronchoscopy: To localize bleeding site, suction clots, balloon tamponade with Fogarty catheter
• Flexible bronchoscopy: Less suitable for massive hemoptysis (cannot suction fast enough) but useful in stable patients

• Gold standard emergency intervention
• Angiography identifies feeding bronchial artery → selective embolization with gelfoam/PVA particles
• Success rate ~85% initial hemostasis
• Recurrence rate 10-30% (recanalization or collateral formation)

• Pneumonectomy/lobectomy: Definitive; reserved for localized disease in physiologically fit patients
• High perioperative mortality (10-30%)

---

VIVA Q7: How do you differentiate upper lobe consolidation/cavity from lower lobe disease on examination?

• Small cavity: Increased resonance (hyper-resonant)
• Large open cavity (>6 cm): Cracked-pot resonance or amphoric resonance
• Cavity with fluid level: Hippocratic succussion splash (sloshing sound when patient is shaken by the shoulders - this sign is actually more for hydropneumothorax)

---

VIVA Q8: What is the NTEP (formerly RNTCP) classification of TB and what drug regimen is used?

• All TB patients in India are now tested with CBNAAT/GeneXpert MTB/RIF before starting treatment
• Daily Fixed-Dose Combinations (FDC) preferred over intermittent regimens
• DOTS (Directly Observed Treatment, Short-course) backbone

---

VIVA Q9: What are the complications of fibrocavitary pulmonary tuberculosis?

---

VIVA Q10: What is the drug sensitivity testing (DST) for TB? Define MDR-TB and XDR-TB.

• Determines whether MTB isolate is sensitive or resistant to anti-TB drugs
• Methods:
  • Phenotypic DST: Growth on drug-containing culture medium (LJ medium, MGIT liquid culture)
  • Genotypic DST: PCR-based; GeneXpert (rpoB gene → rifampicin resistance), LPA (Line Probe Assay - Hain MTBDRplus: detects H + R resistance)

• Previous TB treatment (especially incomplete)
• Contact with known MDR-TB case
• HIV co-infection
• Poor drug absorption (GI disease)
• Countries with high MDR-TB prevalence (India is high-burden)

• Bedaquiline + Pretomanid + Linezolid (BPaL): 6 months - highly effective new regimen
• Older long regimen (18-24 months): Amikacin, levofloxacin, cycloserine, prothionamide, ethambutol, pyrazinamide

---

VIVA Q11: How does diabetes mellitus worsen TB and how does TB affect diabetes?

• Diabetes increases TB risk 3-fold (relative risk)
• Mechanisms:
  • Hyperglycemia impairs neutrophil chemotaxis and phagocytosis
  • Reduced macrophage function and oxidative burst
  • Impaired T-lymphocyte proliferation and IFN-γ production
  • Poor wound healing and reduced tissue repair
  • Diabetic microangiopathy reduces drug delivery to infected tissue
• TB in DM patients: More severe disease, more cavitary disease, more treatment failure, higher mortality

• Active TB causes glucose intolerance through:
  • Cortisol release (stress response) → insulin resistance
  • Cytokine-mediated (TNF-α, IL-6) impairment of insulin signaling
  • Direct pancreatic involvement (rare)
• Rifampicin: Induces CYP2C9 → accelerates metabolism of sulfonylureas → reduced hypoglycemic effect → apparent worsening of DM control

• Screen all TB patients for DM (FBS/PPBS/HbA1c) at diagnosis
• Screen all DM patients for TB (symptoms, annual CXR in endemic areas)
• Insulin preferred over sulfonylureas during ATT (due to rifampicin interaction)
• Tighter glycemic control improves TB outcomes

---

VIVA Q12: What are the signs of a Bronchial Breathing? How do you elicit and interpret them?

• Equal duration of inspiration and expiration (vs. vesicular: 2:1 inspiration to expiration)
• Gap between inspiration and expiration (silent pause - this is the key distinguishing feature)
• High-pitched, harsh, blowing quality
• Expiratory phase audible and equal/louder than vesicular

1. Consolidation (pneumonia, TB) - most common
2. Pulmonary cavity (with consolidated lung around it)
3. Pleural effusion (at upper level of effusion - Skodaic resonance)
4. Collapsed lung with patent bronchus
5. Pulmonary fibrosis (may have altered breath sounds)

---

STANDARD TEXTBOOK REFERENCES

---

TIPS FOR THE VIVA

1. Always start with "This is a case of fibrocavitary lesion of the lung, most likely post-primary pulmonary tuberculosis based on..." - show you can synthesize the findings
2. The tracheal deviation question is a classic trap: In fibrocavitary TB with fibrosis, trachea deviates TOWARD the lesion (not away - that's seen with effusion/tension pneumothorax)
3. Know 4 percussion notes over cavity: Normal resonance (small), hypersonance (medium), cracked-pot resonance (large open), dullness (cavity filled with fluid or pus)
4. Hemoptysis mechanism always asked - know Rasmussen's aneurysm by name
5. MDR-TB definitions change frequently - quote WHO 2022 XDR-TB definition
6. CBNAAT is the first test to order, not just sputum AFB - this shows updated knowledge
7. Diabetes + TB bidirectional relationship - always expected from a final year resident
8. Never forget HIV testing in every TB patient - it is mandatory per NTEP
9. Aspergilloma vs. active TB cavity: Air crescent sign (mobile mass that changes with position) = aspergilloma; tree-in-bud pattern = active bronchogenic spread of TB
10. When asked "differential diagnosis of upper lobe cavity," systematically use the mnemonic: TRAMS - TB, Radionecrosis/Rheumatoid, Abscess, Malignancy (squamous), Systemic vasculitis (Wegener's) + fungi (Aspergillus, Histoplasma)